NextCure updates corporate presentation on LNCB74 trial; no specific data disclosed

NextCure, Inc.

Updated presentation for LNCB74, a clinical-stage candidate, furnished on April 10, 2025.
Company engaging with investment community referencing updated materials.
No new clinical data, enrollment figures, or milestones provided in the filing or exhibit.

item 7.01 item 9.01

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-004651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.